1-20 of 7996 Search Results for

combination-index

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1046.
Published: 15 June 2022
... by Palbociclib plus Rapamycin for 4 days and performed an MTT assay to assess relative viable cell number. We also did a fixed ratio treatment with Palbociclib and Rapamycin, followed by calculation of combination index to determine the nature of their interaction. Finally, we performed Western Blot analysis...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5337.
Published: 15 June 2022
... with Bcl2 inhibitor ABT199. The combination of ABT199 and ASTX660 was synergistic in Loucy cell line with combination index (CI) of 0.14. Cell death was increased to 64±3% in combination v/s 27±0.9% in ABT199. WB showed decreased cIAP2 and increased levels of cleaved caspase 7 and cleaved caspase 9...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3001.
Published: 15 June 2022
... of the combinations HCQ+Ponatinib and HCQ+Rapamycin in the reduction of the cell viability after 24, 48 and 72 hours of simultaneous treatment. Combination index analyses showed a synergic time and dosage-dependent reduction of the cell viability in all the cell lines treated with HCQ+Ponatinib. The combination HCQ...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1840.
Published: 15 June 2022
... index, apoptosis, clonogenic capability, tumor spheroids and fibroblasts/tumor cells microtissues growth. Antitumor effect was confirmed in vivo on heterotopic and orthotropic xenograft PANC1 models in athymic mice. Expression and functional role of TGF-β and downstream epithelial-to-mesenchymal...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2668.
Published: 15 June 2022
... between 50 to 100nM and to belinostat with IC50 values between 100 to 250nM. Combination index analysis of ASTX029 and belinostat by the Chou-Talalay method indicated synergism, with CI values ranging from 0.34 to 0.97. We explored other drug candidates for combinatorial approaches including the BCL-2...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3947.
Published: 15 June 2022
... agent IC50 was calculated to be 1.22uM for ONC201, 51.5uM for darolutamide and >80uM for enzalutamide. In LNCaP, the single agent IC50s are 1.67uM for ONC201, 58.7uM for darolutamide, and 4.05uM for enzalutamide. In 22RV1, the combination index (CI) of 0.38 was obtained when treated with 40uM...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 4064.
Published: 15 June 2022
... concentrations of the drugs. CellTiter Glo was used to perform cell viability assays, and combination index analysis (Combenefit software) revealed the most synergy between the agents occurred at the concentrations of 0.156 uM ONC201 and 0.047 nM lurbinectedin. We are expanding this combination’s efficacy...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2658.
Published: 15 June 2022
... viability was determined with SRB Assay and the combination index was evaluated using Chou-Talalay Method. Flow cytometry was conducted to evaluate cellular apoptosis and cell cycle distribution analysis. In vivo efficacy of NOS and PI3K inhibition was assessed using MpBC PDX models. Transcriptional...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5408.
Published: 15 June 2022
... μM) yielded additive/synergistic cytotoxic effects (combination index < 1) in various HGSOC cell lines, including acquired and de novo PARPi-resistant (PEO1/OlaR, PEO1/OlaJR, and PEO4) and platinum-resistant HGSOC cell lines (OVCAR3), by XTT and colony formation assays. With clinically attainable...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3232.
Published: 15 June 2022
... was evaluated in Pt-sensitive and Pt-resistant EOC and NSCLC cell lines by calculating combination indexes (CI), colony formation assay, apoptosis and DNA damage, as well as on 3D in vitro microtissues obtained by co-culturing cancer cells with normal fibroblasts and in vivo EOC and NSCLC xenograft models...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3476.
Published: 15 June 2022
... organoid model (combination index 0.51). The clinical combination of VS-6766 and defactinib (September 2021 cut-off) has shown an objective response rate (ORR) of 11/24 (46%) across all patients with LGSOC, and an ORR of 64% (7/11) for patients with KRAS mt LGSOC (n=11). In addition to mutations in KRAS...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1847.
Published: 15 June 2022
..., concentrations did not exceed the maximum achievable concentration in plasma (Liston and Davis. 2017. Clinical Cancer Research, 15(14):3489-3498). Synergy = combination index <0.9. ES1 ES2 ES3 ES4 CCT137690 (EC50, uM) 3 3.6 0.3 0.4 CD532 (EC50, uM) 1.8 3.5 0.2 1.1 Doxorubicin...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2997.
Published: 15 June 2022
... by a low combination index, was positively correlated with percent inhibition. These results were confirmed by increased levels of apoptosis as demonstrated by flow cytometry and both early and sustained cell growth inhibition over time in impedance assays. Ongoing studies include additional...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3250.
Published: 15 June 2022
... treatment. Our data suggested that combination of 5FU with UroA or UAS03 significantly reduced cell viability of 5FUR colon cancer cell lines with combination index (CI) less than 1 suggesting their synergism. Moreover, UroA or UAS03 in combination with 5FU significantly inhibited 5FUR colon cancer cell...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2017.
Published: 15 June 2022
... performed to evaluate target selectivity and dependency. In vivo efficacy and safety studies focused on patient-derived xenografts (PDXs) of relapsed OS. TT2-77 xenoline, Saos2, G292, and U2OS cell lines were selected for in vitro experiments. Combination index and Bliss independence analyses demonstrated...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2698.
Published: 15 June 2022
...) synergistically reduced tumor burden in liver metastasis in vitro (combination index < 1 in cell viability assays) and in vivo in mouse xenograft models. A synergistic effect was not observed when KPT-9274 was combined with Palbociclib or Tamoxifen, nor Fulv with other metabolic inhibitors. RNA-Seq analysis...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5468.
Published: 15 June 2022
... cancer cells with ENZ in the presence or absence of SOAT1 inhibitor, avasimibe, and found the combination treatment effectively reduced the level of CEs compared to control, which accompanied inhibition of colony formation and cell proliferation. Combination index value was calculated...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3333.
Published: 15 June 2022
... Combenefit and Calcusyn software. Combination Index (CI) values < 1 indicated synergy, > 1 antagonism. Neratinib IC50 values < 150nM were considered physiologically relevant. Prolonged exposure in vitro efficacy was tested in these cell lines by treating twice weekly with NER +/- DAS until...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2858.
Published: 15 June 2022
.... Compared to CXCL1 expression-low group (RT112 and UMUC-14), CXCL1 expression-high group (T24, 5637, 253J, 253J-BV) tended to show low IC50. Synergistic combination efficacy was observed in NTC-001 in combination with gemcitabine (combination index<1) though not with cisplatin. PK study demonstrated...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2011.
Published: 15 June 2022
.... To mitigate such CDK4/6i resistance in OS, we hypothesized that dual inhibition of CDK4/6 and PI3K pathways will promote cytotoxicity in hyperactivated CDK4/6 OS models. RB+ OS cell lines and a TT2-77 xenoline were evaluated in vitro. Combination index and Bliss independence analyses indicated that inhibition...